Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL3 as adjunctive to a standard pharmaceutical treatment: A double-blind, randomized, placebo-controlled study

American Journal of Gastroenterology

Volumn 105, Issue 10, 2010, Pages 2218-2227

  Tursi, Antonio ^a   Brandimarte, Giovanni ^b   Papa, Alfredo ^c   Giglio, Andrea ^d   Elisei, Walter ^b   Giorgetti, Gian Marco ^e   Forti, Giacomo ^f   Morini, Sergio ^g   Hassan, Cesare ^g   Pistoia, Maria Antonietta ^h   Modeo, Maria Ester ⁱ   Rodino', Stefano ^d   D'Amico, Teresa ^d   Sebkova, Ladislava ^d   Sacca', Natale ^d   Di Giulio, Emilio ^j   Luzza, Francesco ^k   Imeneo, Maria ^k   Larussa, Tiziana ^k   Di Rosa, Salvatore ^l   Annese, Vito ^m   Danese, Silvio ⁿ   Gasbarrini, Antonio ^c   more..

^a Lorenzo Bonomo Hospital   (Italy)

^b Cristo Re Hospital   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d PUGLIESE CIACCIO HOSPITAL   (Italy)

^e S EUGENIO HOSPITAL   (Italy)

^f SANTA MARIA GORETTI HOSPITAL   (Italy)

^g NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^h SAN SALVATORE HOSPITAL   (Italy)

ⁱ POLICLINICO   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k Policlinico Mater Domini   (Italy)

^l Villa Sofia CTO Hospital   (Italy)

^m CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

ⁿ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; BALSALAZIDE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; VSL3; PROBIOTIC AGENT;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; BLOATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL ENDOSCOPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS THERMOPHILUS; ULCERATIVE COLITIS; ULCERATIVE COLITIS DISEASE ACTIVITY INDEX; BIFIDOBACTERIUM; COLITIS, ULCERATIVE; LACTOBACILLUS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; REMISSION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; BIFIDOBACTERIUM; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTOBACILLUS; MALE; MESALAMINE; MIDDLE AGED; PATIENT SELECTION; PROBIOTICS; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; STREPTOCOCCUS THERMOPHILUS; TREATMENT OUTCOME;

EID: 77957831387     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.218     Document Type: Article

References (35)

1. Schwartz M, Cohen R. Optimizing conventional therapy for Inflammatorybowel disease. Curr Gastroenterol Rep 2008; 10: 585-90.
2. Travis S, Stange EF, L é mann M et al. For the European Crohn's andColitis Organisation (ECCO). European evidence-based consensus of themanagement of ulcerative colitis: current management. J Crohn Colitis 2008; 2: 24-62.
3. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenancetreatment in patients with chronic pouchitis: a double-blind,placebo- controlled trial. Gastroenterology 2000; 119: 305-9. (Pubitemid 30621980)
4. Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset withprobiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-9. (Pubitemid 36531796)
5. Tursi A, Brandimarte G, Giorgetti GM et al. Low-dose balsalazide plus ahigh-potency probiotic preparation is more effective than balsalazide aloneor mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.Med Sci Monit 2004; 10: PI126-31. (Pubitemid 39546045)
6. Bibiloni R, Fedorak RN, Tannock GW et al. VSL#3 probiotic-mixtureinduces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539-46. (Pubitemid 41032360)
7. Mallon P, McKay D, Kirk S et al. Probiotics for induction of remission inulcerative colitis. Cochrane Database Syst Rev 2007; 17: CD005573. (Pubitemid 351805347)
8. Moser G. How oft en do patients with IBD have symptom recurrence?Inflamm Bowel Dis 2008; 14 (Suppl 2): S47.
9. Rizzello F, Gionchetti P, D'Arienzo A et al. Oral beclometasone dipropionatein the treatment of active ulcerative colitis: a double-blind placebo-controlledstudy. Aliment Pharmacol Ther 2002; 16: 1109-16. (Pubitemid 34680753)
10. Kornbluth A, Sachar DB, Practice Parameters Committee of the AmericanCollege of Gastroenterology. Ulcerative colitis practice guidelines in adults(update): American College of Gastroenterology, Practice ParametersCommittee. Am J Gastroenterol 2004; 99: 1371-85.
11. Pardi DS, D'Haens G, Shen B et al. Clinical guidelines for the managementof pouchitis. Inflamm Bowel Dis 2009; 15: 1424-31.
12. Mennigen R, Nolte K, Rijcken E et al. Probiotic mixture VSL # 3 protectsthe epithelial barrier by maintaining tight junction protein expression andpreventing apoptosis in a murine model of colitis. Am J Physiol GastrointestLiver Physiol 2009; 296: G1140-9.
13. Reiff C, Delday M, Rucklidge G et al. Balancing Inflammatory, lipid,and xenobiotic signaling pathways by VSL # 3, a biotherapeutic agent,in the treatment of Inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 1721-36.
14. Kruis W, Schütz E, Fric P et al. Double-blind comparison of an oralEscherichia coli preparation and mesalazine in maintaining remission ofulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-8. (Pubitemid 27445670)
15. Rembacken BJ, Snelling AM, Hawkey PM et al. Non-pathogenic Escherichiacoli versus mesalazine for the treatment of ulcerative colitis: a randomisedtrial. Lancet 1999; 354: 635-9.
16. Kruis W, Fric P, Pokrotnieks J et al. Maintaining remission of ulcerativecolitis with the probiotic Escherichia coli Nissle 1917 is as effective as withstandard mesalazine. Gut 2004; 53: 1617-23. (Pubitemid 39434105)
17. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardiiin ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 697-8. (Pubitemid 36688235)
18. Riquelme AJ, Calvo MA, Guzm á n AM et al. Saccharomyces cerevisiaefungemia aft er Saccharomyces boulardii treatment in immunocompromisedpatients. J Clin Gastroenterol 2003; 36: 41-3.
19. Famularo G, Trinchieri V, De Simone C. Inflammatory bowel disease.N Engl J Med 2002; 347: 1982-4.
20. Venturi A, Gionchetti P, Rizzello F et al. Impact on the compositionof the faecal flora by a new probiotic preparation: preliminary data onmaintenance treatment of patients with ulcerative colitis. AlimentPharmacol Ther 1999; 13: 1103-8. (Pubitemid 29374113)
21. Huynh HQ, deBruyn J, Guan L et al. Probiotic preparation VSL#3 inducesremission in children with mild to moderate acute ulcerative colitis: a pilotstudy. Inflamm Bowel Dis 2009; 15: 760-8.
22. Miele E, Pascarella F, Giannetti E et al. Effect of a probiotic preparation(VSL # 3) on induction and maintenance of remission in children withulcerative colitis. Am J Gastroenterol 2009; 104: 437-43.
23. Sood A, Midha V, Makharia GK et al. The probiotic preparation, VSL # 3,induces remission in patients with mild-to-moderately active ulcerativecolitis. Clin Gastroenterol Hepatol 2009; 7: 1202-9.
24. Garud S, Brown A, Cheifetz A et al. Meta-analysis of the placebo responsein ulcerative colitis. Dig Dis Sci 2008; 53: 875-91. (Pubitemid 351379818)
25. Ansari R, Attari F, Razjouyan H et al. Ulcerative colitis and irritable bowelsyndrome: relationships with quality of life. Eur J Gastroenterol Hepatol 2008; 20: 46-50. (Pubitemid 350307488)
26. Hanauer SB. Review article: high-dose aminosalicylates to induce andmaintain remissions in ulcerative colitis. Aliment Pharmacol Ther 2006; 24(Suppl 3): 37-40.
27. Madsen K. Probiotics in critically ill patients. J Clin Gastroenterol 2008; 42(Suppl 3, Pt 1): S116-8.
28. Wallace JL, Vergnolle N, Muscar á MN et al. Enhanced anti-Inflammatoryeffects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology 1999; 117: 557-66. (Pubitemid 29409241)
29. Greenfield SM, Punchard NA, Teare JP et al. Review article: the mode ofaction of the aminosalicylates in Inflammatory bowel disease. AlimentPharmacol Ther 1993; 7: 369-83.
30. Schlee M, Harder J, Koten B et al. Probiotic lactobacilli and VSL # 3 induceenterocyte beta-defensin 2. Clin Exp Immunol 2008; 151: 528-35.
31. Madsen K, Cornish A, Soper P et al. Probiotic bacteria enhance murineand human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-91. (Pubitemid 32822573)
32. Caballero-Franco C, Keller K, De Simone C et al. The VSL # 3 probioticformula induces mucin gene expression and secretion in colonic epithelialcells. Am J Physiol Gastrointest Liver Physiol 2007; 292: G315-22. (Pubitemid 46090273)
33. Clayton TA, Baker D, Lindon JC et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affectinghuman drug metabolism. Proc Natl Acad Sci USA 2009; 106: 14728-33.
34. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factorprevents intestinal Inflammatory disease. Nature 2008; 453: 620-5.
35. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immuneresponses during health and disease. Nat Rev Immunol 2009; 9: 313-23.